Propanc Biopharma Inc Stock Other OTC
Equities
US74346N1072
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 559K |
---|---|---|---|---|---|
Net income 2022 | -2M | Net income 2023 | -2M | EV / Sales 2022 | - |
Net Debt 2022 | 1.09M | Net Debt 2023 | 536K | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.07
x | P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 07-10-14 | |
Julian Kenyon
FOU | Founder | 77 | 07-10-14 |
Klaus Kutz
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 07-10-14 | |
Julian Kenyon
FOU | Founder | 77 | 07-10-14 |
Josef Zelinger
BRD | Director/Board Member | 74 | 20-12-22 |
1st Jan change | Capi. | |
---|---|---|
+20.39% | 127B | |
+24.43% | 117B | |
+25.44% | 27.67B | |
-18.11% | 20.33B | |
-15.17% | 16.79B | |
-14.88% | 15.63B | |
+12.67% | 14.84B | |
-47.10% | 14.65B | |
+56.25% | 14.43B |